FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013
Executive Summary
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013.